Biora Therapeutics Reports Submission Of IND Application To US FDA For BT-600 Program
Portfolio Pulse from Benzinga Newsdesk
Biora Therapeutics has submitted an Investigational New Drug (IND) application to the US FDA for its BT-600 program. The application supports the next phase of development of BT-600, a drug/device combination designed to use Biora's NaviCap™ ingestible drug delivery device with a proprietary liquid formulation of tofacitinib, for the treatment of moderate to severe ulcerative colitis.
September 25, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biora Therapeutics has submitted an IND application to the FDA for its BT-600 program, which could potentially advance the company's drug development process.
The submission of an IND application to the FDA is a significant step in the drug development process. If approved, it could potentially lead to the advancement of Biora's BT-600 program, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100